@inbook{a496c6be9b054ecf9acdb445173b849d,
title = "Human behavioral pharmacology of psychedelics",
abstract = "The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an overview of the human behavioral pharmacology of psychedelics focusing on three prototypic classic psychedelics—psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT). A brief historical overview of the classic psychedelics and naming and drug classification is first specified. Next, special considerations in the conduct of human behavioral pharmacology work with psychedelics is described including the role of set and setting, mystical experience measurement, the use of effective blinding and placebos, and the abuse liability of psychedelics. Following, a description of the subjective, physiological, and clinical effects of psilocybin, LSD, and DMT is provided. This body of work clearly documents a unique and complex collection of subjective effects following psychedelic use, both during acute drug administration and as related to long-term behavior change following use. Clinical research demonstrates potential therapeutic utility with early phase clinical trials showing positive and enduring effects in many difficult-to-treat conditions including treatment-resistant depression, alcohol use disorder, and cigarette smoking. Future work in this newly reemerged field is needed to reveal mechanisms of behavior change in psychedelic drug action. Behavioral pharmacology is ultimately well served to provide this direction answering questions at the intersection of environment and pharmacology.",
keywords = "DMT, Hallucinogen, LSD, Mystical experience, Psilocybin, Psychedelic, Treatment",
author = "Strickland, {Justin C.} and Johnson, {Matthew W.}",
note = "Funding Information: Support for effort by M.W.J. was provided by the Johns Hopkins Center for Psychedelics and Consciousness Research which is funded by the Steven and Alexandra Cohen Foundation and the Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie Collaborative. Support for effort by J.C.S. was provided by the National Institute on Drug Abuse Grant T32DA07209. Funding Information: Support for effort by M.W.J. was provided by the Johns Hopkins Center for Psychedelics and Consciousness Research which is funded by the Steven and Alexandra Cohen Foundation and the Tim Ferriss, Matt Mullenweg, Craig Nerenberg, and Blake Mycoskie Collaborative. Support for effort by J.C.S. was provided by the National Institute on Drug Abuse Grant T32DA07209. M.W.J. has served as a paid consultant for AJNA Labs LLC, AWAKN Life Sciences Inc. Beckley Psychedelic Ltd. Entheogen Biomedical Corp. Field Trip Psychedelics Inc. Mind Medicine Inc. Otsuka Pharmaceutical Development & Commercialization Inc. and Silo Pharma, Inc. J.C.S. has no conflicts of interest to declare. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = jan,
doi = "10.1016/bs.apha.2021.10.003",
language = "English (US)",
isbn = "9780323915267",
series = "Advances in Pharmacology",
publisher = "Academic Press Inc.",
pages = "105--132",
editor = "Jun-Xu Li",
booktitle = "Behavioral Pharmacology of Drug Abuse",
}